Platelet Rich Plasma VS Platelet Fibrin Plasma in Treatment of Diabetes Related Wound：a Randomized Controlled Trial

Inclusion criteria

• The patient is aged 18-80 years old;
• Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;
• diabetes wounds with poor healing or prolonged healing need standard wound treatment;
• There is no disseminated infection or the disseminated infection has been controlled;
• After preparing the wound bed, the condition for using platelet plasma to close the wound is met;
• Voluntarily sign an informed consent form;

Exclusion criteria

• Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;
• Severe ischemia of the wound surface, unable to seek medical attention or not yet corrected;
• Uncontrolled systemic or disseminated infections;
• Blood glucose is out of control or not yet effectively controlled;
• Blood system diseases with uncorrected coagulation dysfunction or platelet dysfunction;
• There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented;
• Platelets ≤ 80 × 10^9, hemoglobin<90g/L;
• Patients with advanced malignant tumors;
• Active period of autoimmune diseases;
• The patient is unable to cooperate or has mental disorders;
• According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.